
Encore Capital Group, Inc. (ECPG) Q2 2026 Earnings Call Transcript
Encore Capital Group, Inc. (ECPG) Q2 2026 Earnings Call Transcript
آخرین اخبار مالی و اقتصادی، تحولات بازار، گزارشها و تحلیلهای بازارهای مالی را در PipVero دنبال کنید.

Encore Capital Group, Inc. (ECPG) Q2 2026 Earnings Call Transcript

Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript

Dine Brands Global reported Q2 2026 revenue above expectations, but EPS and adjusted EPS missed analyst estimates. While DIN remains objectively cheap on both absolute and relative valuation, persistent declines in profitability and rising net debt temper enthusiasm. Growth in IHOP system-wide sales and dual-branded locations offers long-term opportunity, but near-term cash flow and margin pressures persist.

Bed Bath & Beyond, soon Neighborhood Intelligence, is a qualitative turnaround bet centered on CEO Marcus Lemonis's ambitious multi-pillar strategy. Lemonis envisions a synergistic ecosystem spanning retail, financial, and home services, but customer retention and cross-sell logic remain unproven and historically fraught. The investment case is highly speculative; the grand strategy and basic turnaround both face daunting execution risks with little evidence of early traction.

Vast, a Chinese artificial-intelligence unicorn backed by technology titans Alibaba and Baidu, is in talks with investors to get fresh capital, people familiar with the matter say.

ThredUp Inc. (TDUP) Q2 2026 Earnings Call Transcript

Corpay, Inc. (CPAY) Q2 2026 Earnings Call Transcript

Taboola told investors its quarter was strong and raised its full-year ex-TAC gross profit outlook. The same release cut 2026 revenue and non-GAAP net income guidance -- and the stock fell.

Exelixis NASDAQ: EXEL reported second-quarter 2026 revenue of approximately $629 million, including $573 million in cabozantinib franchise net product revenue, as the company prepared for a potential late-year launch of zanzalintinib in colorectal cancer and advanced a broader development program for the drug candidate.

Western Digital Corporation (WDC) Q4 2026 Earnings Call Transcript

SiTime Corporation (SITM) Q2 2026 Earnings Call Transcript

Rigel Pharmaceuticals in-licensed Veppanu, a drug for the treatment of certain breast cancer patients, targeting a $1B market, with revenues expected as early as Q3'26. Q2'26 saw strong sales growth from Tavalisse and Rezlidhia, offsetting Gavreto's middling performance. RIGL guides $285M–$295M 2026 revenues, excluding Veppanu upside. Upcoming R289 phase 1b data for LR-MDS and future readouts from Veppanu and Rezlidhia trials provide additional growth catalysts.

Beach Energy posted an annual profit on Thursday, a sharp turnaround from a year-earlier loss, although shares of the Australian oil and gas producer slipped more than 6% as investors focused on its soft production outlook.

mFLUSIVA becomes Moderna's fifth approved product globally and fourth FDA-approved product Company expects supply to be available in select retailers in the coming weeks CAMBRIDGE, MA / ACCESS Newswire / August 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mFLUSIVA® (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older. This approval follows unanimous recommendations from the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) supporting mFLUSIVA for adults 50 years of age and older.

Vancouver, British Columbia--(Newsfile Corp. - August 5, 2026) - Kingman Minerals Ltd. (TSXV: KGS) (OTCQB: KGSSF) (FSE: 47A1) ("Kingman" or the "Company") announces that its Board of Directors has approved the Company's election to rely on Coordinated Blanket Order 51-933 - Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (the "Blanket Order") issued by the Canadian Securities Administrators ("CSA").